Enzychem Lifesciences Corporation (183490.KQ)
KRW 1211.0
(-3.66%)
KRW 1211.0
(-3.66%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 16.91 Billion KRW | -63.07% |
| 2022 | 45.81 Billion KRW | -21.59% |
| 2021 | 58.42 Billion KRW | 13.84% |
| 2020 | 51.31 Billion KRW | 368.65% |
| 2019 | 10.95 Billion KRW | 33.08% |
| 2018 | 8.22 Billion KRW | -32.78% |
| 2017 | 12.24 Billion KRW | 26.05% |
| 2016 | 9.71 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 14.83 Billion KRW | -12.31% |
| 2024 Q2 | 13.43 Billion KRW | -9.44% |
| 2023 Q1 | 19.89 Billion KRW | -56.57% |
| 2023 FY | 16.91 Billion KRW | -63.07% |
| 2023 Q3 | 20.8 Billion KRW | 28.29% |
| 2023 Q2 | 16.21 Billion KRW | -18.5% |
| 2023 Q4 | 16.91 Billion KRW | -18.67% |
| 2022 Q2 | 63.73 Billion KRW | 7.18% |
| 2022 Q1 | 59.46 Billion KRW | 1.78% |
| 2022 Q4 | 45.81 Billion KRW | -27.63% |
| 2022 FY | 45.81 Billion KRW | -21.59% |
| 2022 Q3 | 63.29 Billion KRW | -0.68% |
| 2021 Q4 | 58.42 Billion KRW | 1.29% |
| 2021 Q2 | 55.65 Billion KRW | 1.37% |
| 2021 Q3 | 57.67 Billion KRW | 3.65% |
| 2021 Q1 | 54.89 Billion KRW | 6.97% |
| 2021 FY | 58.42 Billion KRW | 13.84% |
| 2020 Q4 | 51.31 Billion KRW | 128.63% |
| 2020 FY | 51.31 Billion KRW | 368.65% |
| 2020 Q1 | 12.16 Billion KRW | 11.05% |
| 2020 Q3 | 22.44 Billion KRW | 26.13% |
| 2020 Q2 | 17.79 Billion KRW | 46.34% |
| 2019 Q4 | 10.95 Billion KRW | -2.3% |
| 2019 FY | 10.95 Billion KRW | 33.08% |
| 2019 Q1 | 11.48 Billion KRW | 39.53% |
| 2019 Q3 | 11.2 Billion KRW | -1.13% |
| 2019 Q2 | 11.33 Billion KRW | -1.27% |
| 2018 Q1 | - KRW | -100.0% |
| 2018 FY | 8.22 Billion KRW | -32.78% |
| 2018 Q2 | 13.02 Billion KRW | 0.0% |
| 2018 Q3 | 12.15 Billion KRW | -6.66% |
| 2018 Q4 | 8.22 Billion KRW | -32.29% |
| 2017 FY | 12.24 Billion KRW | 26.05% |
| 2017 Q4 | 12.24 Billion KRW | 0.0% |
| 2016 FY | 9.71 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 53.19 Billion KRW | 68.197% |
| CMG Pharmaceutical Co., Ltd. | 40.02 Billion KRW | 57.734% |
| Celltrion Pharm, Inc. | 264.97 Billion KRW | 93.615% |
| Huons Global Co., Ltd. | 407.28 Billion KRW | 95.846% |
| DongKook Pharmaceutical Co., Ltd. | 263.36 Billion KRW | 93.576% |
| Humedix Co., Ltd. | 21.91 Billion KRW | 22.797% |
| Boditech Med Inc. | 30.48 Billion KRW | 44.501% |
| EuBiologics Co., Ltd. | 67.82 Billion KRW | 75.055% |
| FutureChem Co.,Ltd | 8.91 Billion KRW | -89.699% |
| Huons Co., Ltd. | 206.87 Billion KRW | 91.822% |
| BNC Korea Co., Ltd. | 21.94 Billion KRW | 22.907% |
| AptaBio Therapeutics Inc. | 38.19 Billion KRW | 55.7% |